BioLife Solutions CEO Sells Shares Amid Insider Activity
BioLife Solutions President and CEO Roderick De Greef sold 2,775 shares.
Key Points
- BioLife Solutions CEO Roderick De Greef sold 2,775 shares on June 18, 2026, at $26.04 each, totaling $72,261.
- BioLife Solutions, trading at $26.04 on Tuesday, has a market cap of $1.27 billion and a forward P/E of 89.79.
- Analysts from firms like HC Wainwright & Co. maintain a 'buy' rating with price targets up to $33.00.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
BioLife Solutions, Inc. (NasdaqCM: BLFS) saw insider selling activity as its President and CEO, Roderick De Greef, sold 2,775 shares on June 18, 2026. The shares were sold at a price of $26.04 each, bringing the total transaction value to $72,261. This sale was not part of a pre-planned trading program.
Insider Buying and Selling at BioLife Solutions, Inc.
On June 18, 2026, several executives at BioLife Solutions, including President and CEO Roderick De Greef, sold shares of the company. De Greef sold 2,775 shares at $26.04 each, while other executives like Chief Marketing Officer Todd Berard and Chief Financial Officer Troy Wichterman also sold shares at the same price. These transactions were not under Rule 10b5-1 plans.
Other Institutional Activity in BioLife Solutions
In recent institutional moves, T. Rowe Price Investment Management, Inc. increased its holdings by 1,325,522 shares, ending with 6,506,346 shares valued at approximately $124.1 million, marking a 25.6% increase. BlackRock, Inc. added 190,151 shares, bringing its total to 6,101,765 shares worth about $116.4 million, a 3.2% increase. Casdin Capital, LLC maintained its position with 5,957,165 shares valued at $113.7 million. Invesco Ltd. reduced its stake by 1,583,659 shares, now holding 2,348,532 shares worth $44.8 million, a 40.3% decrease. Meanwhile, Vanguard Capital Management LLC opened a new position with 1,917,708 shares valued at $36.6 million.
BioLife Solutions, Inc. Stock Down 31.6%
Shares of BioLife Solutions traded near $26.04 on Tuesday. The company, with a market cap of about $1.27 billion, has a forward P/E ratio of 89.79 and a beta of 1.971. The stock's 52-week range is between $17.86 and $29.62. It has a 50-day moving average of $23.28 and a 200-day moving average of $23.98. The company's current ratio stands at 7.299, with a quick ratio of 5.153 and a debt-to-equity ratio of 3.991.
$BLFS stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
BioLife Solutions reported revenue of $101.66 million, showing a growth of 24.7%. The company, however, posted a net margin of -2.913% and a return on equity of -3.094%, with an EPS of -$0.24. The next earnings report is expected on August 6, 2026.
Analysts Set New Price Targets
On August 8, 2025, HC Wainwright & Co. maintained its 'buy' rating for BioLife Solutions, setting a price target of $32.00. The consensus among 10 analysts is a 'buy', with a mean price target of $32.30.
About BioLife Solutions, Inc.
BioLife Solutions, Inc., headquartered in Bothell, Washington, develops and sells bioproduction products and services for the cell and gene therapy industry. The company offers biopreservation media products, bioproduction products, and automated cell processing machines. It also provides shipping containers for temperature-sensitive biologics. Led by CEO Roderick De Greef, BioLife operates globally, serving markets in the U.S., Europe, the Middle East, and Africa.
Bottom Line
The insider sale by BioLife Solutions' CEO is part of a broader pattern of executive transactions within the company. Investors keep a close eye on such moves to gauge insider confidence. Despite the selling activity, analysts remain optimistic with 'buy' ratings, reflecting confidence in the company's growth potential. Remember, insider transactions are reported after the fact and may not indicate future stock performance.
Get BioLife Solutions, Inc. alerts
New 13F filings, insider trades, and analyst moves on $BLFS, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.